DeAnne Aguirre, a director on the board of Hercules Capital, Inc. (NASDAQ: HTGC), bought 7,317 shares of the company's common stock on March 26, 2026, according to a recent SEC filing. The shares were acquired at an average price of $14.35, with execution prices reported between $14.31 and $14.39, for a total outlay of $104,998.
The filing states that Aguirre received the shares by electing to take stock in lieu of cash for her director compensation. After the transaction, her direct ownership stands at 10,749 shares. She also holds an indirect interest of 20,086 shares through the Aguirre Family 2004 Trust, as reflected in the filing.
Separately, Hercules Capital provided preliminary estimates for its fourth-quarter and year-end financial metrics. The firm reported a net asset value per share in a range of $12.10 to $12.16 as of December 31, 2025. That preliminary NAV range is higher than the NAV per share of $12.05 the company reported on September 30, 2025.
In a related financing development, Savara Inc. amended a loan agreement with Hercules Capital that, contingent upon FDA approval of the drug MOLBREEVI, would make up to an additional $75 million available to Savara. When combined with a previously arranged financing agreement, the amendment could increase Savara's access to about $150 million in non-dilutive capital.
Market participants have taken note of Hercules Capital's portfolio composition. Piper Sandler revised its coverage of the company, downgrading the stock from Overweight to Neutral and lowering the price target to $17.50 from $20.50. The firm cited the company's 35% exposure to the software sector as a key factor in its reassessment, noting the sector faces risks tied to artificial intelligence disruption.
Meanwhile, a short report from Hunterbrook questioned the valuation of Hercules Capital's software-related debt and raised concerns about the sustainability of the company's dividend. The Hunterbrook report highlighted that 35% of Hercules Capital's loan portfolio is exposed to software debt, and the issuer of the report disclosed a short position in Hercules Capital while maintaining long positions in comparable securities.
These disclosures and third-party analyses occur alongside the insider purchase by a sitting director, an action the SEC filing attributes to a compensation election rather than an independent open-market investment decision. The filing documents the post-transaction holdings and the mechanics of the stock election, while the company's preliminary NAV update and the Savara loan amendment provide additional context on Hercules Capital's recent activity.
Lookahead notes
The SEC filing documents and the company's preliminary NAV statement are the primary sources for the transaction and valuation figures cited here. The amended Savara loan commitment is conditional on regulatory approval of MOLBREEVI. Piper Sandler's downgrade and Hunterbrook's short report reflect third-party assessments of portfolio exposure and dividend durability; both reference the stated 35% software debt concentration in Hercules Capital's loan book.